Call for Abstracts

Abstract Submission Period

August 21st (Thu.) – September 25th (Thu.), 2025 (JST)

Ethics Reviews

Medical research must comply with all declarations, laws and regulations, government ordinances, ministerial ordinances, guidelines, and notifications related to research ethics.

When submitting an abstract to JUA2026, prior approval of the ethical review by your institution’s ethics committee is mandatory.

* In principle, both interventional studies and observational studies must obtain approval by the head of the institution based on a review by the ethics review committee and must obtain informed consent. Please note that case reports not intended for research purposes are exempt from this requirement.

The Japanese Urological Association (JUA) has established an Ethics Review Subcommittee under its Ethics Committee. This subcommittee will conduct ethics reviews exclusively for abstracts submitted to the JUA Annual Meeting, serving as a relief measure for members belonging to research institutions that do not have an ethics review committee as stipulated by the Ethical Guidelines for Medical and Biological Research Involving Human Subjects, Ministry of Education, Culture, Sports, Science and Technology (MEXT), Ministry of Health, Labour and Welfare (MHLW), Ministry of Economy, Trade and Industry (METI) (established March 23, 2021), and for presenters from overseas. The subcommittee will review studies that fall under the ethical guidelines and which have no conflict of interest.

However, if the principal investigator (representative investigator) or any co-investigator belongs to an institution with an established ethics review committee, the study is not eligible for review by the JUA Ethics Review Subcommittee.

If you would like to apply for ethics review by the JUA Ethics Review Subcommittee, please follow the instructions below and complete the application procedure well in advance so as to be in time for the abstract submission period.

Review Fee

JPY 30,000 (tax included)

* Please note that bank transfer fees must be paid by the applicant.

Application Procedure

If you wish to have a study reviewed by the JUA Ethics Review Subcommittee, please download the form below and send it as an email attachment to JUA 2026 Management Office (pr_jua2026@c-linkage.co.jp) .
Please use the subject line “[Application] Ethics Review” when sending your email.
Ensure that the review fee is transferred to the designated bank account in advance. Be sure to include the transfer date and name of payer in the body of your email. Please note that once the review fee has been transferred, it cannot be refunded under any circumstances.

Application Form

Abstract Submission Requirements

There will be 4 sessions at JUA2026.

1. International Best Presentation Award (Oral)*
2. International Session Oral
3. International Session e Poster (Moderated)
4. International Session Video

*The International Best Presentation Award winners will be entitled to a grant. If you would like to apply for the grant, please select “International Best Presentation Award” in the abstract submission form

International Best Presentation Award

The International Best Presentation Award winners will be entitled to a grant. If you would like to apply for the grant, please select “International Best Presentation Award” in the abstract submission form.

Eligibility for Award

This award is limited to physicians and researchers from overseas who are not full members of the Japanese Urological Association (including PhDs, but excluding those affiliated with pharmaceutical companies).
Award winners will be recognized at the International Party on the evening of the first day of presentations. If you do not attend the award ceremony, you will not be awarded a certificate.
All aspects of abstracts submitted for the International Best Presentation Award—including the abstract, presentation slides, and oral presentation—must be in English.
If your abstract is not selected for the award, it may be presented as either an oral or poster presentation in the International Session. The final session assignment will be at the discretion of the Congress President.
Please note that if the presenter is changed, the abstract will no longer be eligible for selection.

Submission Requirements

Language	English
Length	(Abstract Title) Within 160 characters (Abstract Body) Within 1,600 characters * Please include objectives, methods, results and conclusions.
Authors	Maximum of 13 authors (including the first author) * Please list the presenter as the first author.

Please note

You may choose a topic category of your presentation from the list. The final decision, however, is the discretion of the congress president.
When printing in the Program, we will not edit submitted abstracts. Therefore, you should be mindful of spell checking and grammatical correctness in your submission.
Once registration deadline is closed, no change requests of the title, co-authors, or any others may be accepted.
Ethical consideration must be provided with your presentation, such as when animals are used in your clinical samples.

COI (Conflict of Interest) Disclosure Declaration

Declaration is required if the total annual amount received during the three years prior to the abstract registration date exceeds the prescribed total amount listed below. For all authors, including the first author and any co-authors, please select whether the situation is applicable (“Yes” or “No”) for each item. If “Yes,” please enter the name of the company and the year(s) in which the prescribed total amount was exceeded on the Abstract Registration System screen. If there are co-authors whose details of declaration are still being confirmed, please select “Confirmation in progress” and register by Wednesday, April 22, 2026.

Item	Amount, etc.
Remuneration	JPY 1 million or more per year from a single company or organization
Profit from stocks	JPY 1 million or more per year from a single company, or holding 5% or more of the company’s shares
Patent royalties	JPY 1 million or more per year for each patent
Lecture fees	JPY 500,000 or more in total per year from a single company or organization
Manuscript fees	JPY 500,000 or more in total per year from a single company or organization
Total amount of research funds and grants, etc.	Contract research funding of JPY 1 million or more actually allocated from a single company or organization for medical research (collaborative research, commissioned research, clinical trials, etc.), where the declarant can substantially determine the use of funds
Total amount of scholarship funds (incentives), etc.	Scholarship funds of JPY 1 million or more actually allocated from a single company or organization to the department sharing the funds, to which the declarant belongs (course, division, or laboratory, etc.), where the declarant can substantially determine the use of funds
Endowed courses funded by a private company, etc.	Endowments of JPY 1 million or more actually allocated, where the declarant can substantially determine the use of funds
Receipt of travel expenses, gifts, etc.	JPY 500,000 or more from a single company or organization

International Session Topic Categories

1	Adrenals	12	Neuro-urology
2	Upper tract benign disease	13	Incontinence
3	Kidney transplantation	14	Infertility
4	Renal tumors	15	Andrology
5	Urothelial tumors	16	Sexual dysfunction
6	Urinary reconstruction	17	Infectious disease
7	Prostate cancer	18	Stones
8	Testis tumors	19	Trauma and emergencies
9	Penile cancer	20	Pediatric urology
10	Male LUTS	21	Urethroplasty and genital reconstruction
11	Female Urology	22	Others

Acceptance Notice

Abstracts will be reviewed by the Organizing Committee. Acceptance of abstracts will be notified by e-mail to the first/presenting author by December, 2025.

The decision of the Organizing Committee is final.

All abstracts accepted will be published in the program book that will be distributed to congress attendees. It will also be placed in the congress app.

Abstract Submission Page

Submit your abstract here

Inquiries for Abstract Submission

Management Office

c/o Convention Linkage, Inc.

E-mail：pr_jua2026@c-linkage.co.jp